Rationale:
Despite the availability of effective inhaled medications, 15% of asthma patients remain
uncontrolled on medium to high dose inhaled corticosteroids (ICS) and LABA, comprising
difficult-to-treat asthma and severe refractory asthma groups. GINA guidelines stress the
importance of assessing adherence and technique before step-up treatment due to
associated risks and costs.
Research underscores the efficacy and cost-effectiveness of investing in adherence and
technique support, particularly in this population. However, there is limited
understanding of ICS adherence during biologic therapy, despite its increasing use.
Studies on biologics like mepolizumab suggest associations between ICS adherence and
improved outcomes, while data on others like benralizumab are less conclusive.
Indeed, non-adherence and poor technique is widely reported in patients with all
severities of asthma and is associated with increased morbidity and economic burden.
Objectively assessing and enhancing adherence remains one of the major challenges for
physicians, pharmacists and nurses. Limited studies on digital tools for adherence
management exist, particularly for pMDIs in combination with spacers. Digital
technologies are promising in addressing these challenges, but studies on devices capable
of objectively measuring adherence and technique, especially in patients using pMDIs, are
lacking. The Smart AeroChamber® device presents an innovative solution, showing potential
in clinical trials for asthma and COPD. The Smart AeroChamber® is a CE-certified device.
However, its application in severe asthma patients on biologics remains unexplored,
presenting an opportunity to enhance adherence support and treatment outcomes in this
cost-sensitive population.
The aim:
This study aims to evaluate the feasibility of using a Smart Spacer device in patients
with severe asthma who are on biologic therapy. The research aims to achieve several
objectives:
Assess medication adherence patterns and inhaler technique using the Smart Spacer
device and compare the data with traditional adherence measures, such as the Test of
Adherence to Inhalers (TAI), and an inhalation technique checklist.
Evaluate the association between adherence measured by the Smart Spacer device and
various clinical outcomes including exacerbations, use of short-acting beta agonists
(SABA) and oral corticosteroids (OCS), Fractional exhaled Nitric Oxide (FeNO)
results, blood eosinophil count, and asthma control questionnaire (ACQ) scores.
Assess the usability and satisfaction of patients and healthcare providers with the
Smart Spacer device, using the System Usability Scale (SUS).
Study Design:
This study adopts a prospective, observational design.
Inclusion Criteria:
Participants eligible for inclusion are adults aged over 18 years, diagnosed with severe
asthma by a physician according to GINA guidelines. They must be using a biologic
medication (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab or tezepelumab)
and medium or high dose ICS + LABA with or without LAMA and/or SABA via pMDI in
combination with a spacer. Additionally, participants must be willing to provide informed
consent.
Exclusion Criteria:
Participants are excluded from participation when they are unable to sufficiently
understand and read the Dutch language, being pregnant or being terminally ill.
Sample Size:
The study aims to include a total of 110 patients.
Setting:
The study is conducted in five severe asthma clinics across various regions of the
Netherlands (Medical Center Leeuwarden, Martini Hospital Groningen, Isala Zwolle, Sint
Franciscus Gasthuis, and University Medical Centrer Groningen).
Baseline Assessment:
Participants undergo characterization during an intake visit to the severe asthma clinic,
including demographic data, medical history, spirometry tests, FeNO measurement, blood
eosinophil count, ACQ assessment, adherence evaluation using TAI, and inhaler technique
assessment via checklist. Subsequently, participants receive two fully charged smart
spacers, one for each period of three months, along with instructions for use.
Follow-up:
After 4 weeks, participants are contacted to check the functionality of the smart spacer
and receive assistance if needed. A follow-up call at 3-months and 9-months into the
study remind participants to switch to the next smart spacer. A physical visit is
scheduled at the 6-month mark for further assessment, including ACQ administration and
collection of smart spacers for replacement.
End of Study Assessment:
At the end of the 12-month study period, participants undergo a final physical visit for
assessment of various parameters including FeNO, blood eosinophil count, lung function,
ACQ score, inhaler technique, and documentation of exacerbations and OCS use. Smart
spacer data analysis is conducted centrally, and feedback is provided to study sites.
Additionally, usability and satisfaction surveys are completed by patients and study
nurses.
